The 30-month stay under the Hatch-Waxman Act lets brand drug companies delay generic approval by triggering patent lawsuits. While designed to protect innovation, it's often used to extend monopolies, costing consumers billions annually.
Read More
Landmark court decisions in generic patent law shape how quickly affordable drugs reach patients. From Amgen v. Sanofi to Amarin v. Hikma, these rulings define the line between innovation and competition-and directly impact drug prices.
Read More